PMID- 29274733 OWN - NLM STAT- MEDLINE DCOM- 20191108 LR - 20191210 IS - 1573-2509 (Electronic) IS - 0920-9964 (Linking) VI - 197 DP - 2018 Jul TI - BDNF as a marker of response to cognitive remediation in patients with schizophrenia: A randomized and controlled trial. PG - 458-464 LID - S0920-9964(17)30754-5 [pii] LID - 10.1016/j.schres.2017.12.002 [doi] AB - BACKGROUND: Brain-derived neurotrophic factor (BDNF) is considered to be a putative biomarker for cognitive recovery in schizophrenia. However, current evidence is still scarce for pharmacological treatments, and the use of BDNF as a biomarker has only been tested once with cognitive remediation treatment (CRT). METHODS: A randomized and controlled trial (NCT02341131) with 70 schizophrenia outpatients and 15 healthy volunteers was conducted. The participants with schizophrenia were randomly assigned to either CRT or the control group. All the participants were assessed in terms of cognition, quality of life, and their serum BDNF levels at both baseline and after the intervention. Additionally, comparisons of the effects of the different genotypes of the Val66Met polymorphism at the BDNF gene on the outcome variables were also performed. RESULTS: The patients in the CRT group presented with improvements in both cognition and quality of life. However, no significant changes were detected in the serum levels of BDNF. Interestingly, we found a significant positive interaction effect between the serum BDNF levels and the different BDNF genotypes. The Val/Val group showed significantly higher serum levels after the CRT treatment. However, the interaction among the serum BDNF levels, the BDNF genotypes and the treatment condition was not statistically significant. CONCLUSIONS: The replication of the previous finding of increased serum BDNF levels after cognitive remediation in clinically stable individuals with schizophrenia was not achieved. However, our data indicated that genetic variability may be mediating serum BDNF activity in the context of CRT. CI - Copyright (c) 2017 Elsevier B.V. All rights reserved. FAU - Penades, Rafael AU - Penades R AD - Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. Electronic address: rpenades@clinic.ub.es. FAU - Lopez-Vilchez, Irene AU - Lopez-Vilchez I AD - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Hemotherapy and Hemostasis, Centre for Biomedical Diagnosis (CDB), Hospital Clinic, Barcelona, Spain. FAU - Catalan, Rosa AU - Catalan R AD - Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. FAU - Arias, Barbara AU - Arias B AD - Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Department of Anthropology, Faculty of Biology and Biomedicine Institute, University of Barcelona, Spain. FAU - Gonzalez-Rodriguez, Alexandre AU - Gonzalez-Rodriguez A AD - Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. FAU - Garcia-Rizo, Clemente AU - Garcia-Rizo C AD - Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. FAU - Masana, Guillem AU - Masana G AD - Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. FAU - Ruiz, Victoria AU - Ruiz V AD - Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. FAU - Mezquida, Gisela AU - Mezquida G AD - Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. FAU - Bernardo, Miquel AU - Bernardo M AD - Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clinic de Neurociencies (ICN), Hospital Clinic, Barcelona, Spain. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20171221 PL - Netherlands TA - Schizophr Res JT - Schizophrenia research JID - 8804207 RN - 0 (Biomarkers) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 7171WSG8A2 (BDNF protein, human) SB - IM MH - Adult MH - Biomarkers/blood MH - Brain-Derived Neurotrophic Factor/*blood/genetics MH - Cognitive Dysfunction/etiology/*therapy MH - Cognitive Remediation/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Outcome Assessment, Health Care MH - Quality of Life MH - Schizophrenia/*blood/complications/*therapy OTO - NOTNLM OT - BDNF OT - Biomarker OT - Cognitive remediation OT - Genotype OT - Neuroplasticity OT - Schizophrenia EDAT- 2017/12/25 06:00 MHDA- 2019/11/09 06:00 CRDT- 2017/12/25 06:00 PHST- 2017/07/01 00:00 [received] PHST- 2017/12/01 00:00 [revised] PHST- 2017/12/10 00:00 [accepted] PHST- 2017/12/25 06:00 [pubmed] PHST- 2019/11/09 06:00 [medline] PHST- 2017/12/25 06:00 [entrez] AID - S0920-9964(17)30754-5 [pii] AID - 10.1016/j.schres.2017.12.002 [doi] PST - ppublish SO - Schizophr Res. 2018 Jul;197:458-464. doi: 10.1016/j.schres.2017.12.002. Epub 2017 Dec 21.